Observational studyWorld journal of surgical oncology2026
Relationship between ABO blood group and lymph node metastasis in colon cancer: a retrospective cohort study.
Observational study in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeColorectal cancer is the third most common cancer and the second leading cause of cancer-related deaths worldwide, according to GLOBOCAN 2022. Lymph node metastasis is a well-recognized prognostic factor in colorectal cancer. While the relationship between ABO blood group, Rhesus (Rh) type, and lymphatic spread has been studied in other gastrointestinal tumors, limited research exists on colorectal cancer. This study primarily aimed to investigate the association between lymph node metastasis and ABO blood group, as well as the relationship between microsatellite instability (MSI) and ABO blood group.
methods. A retrospective observational cohort study was conducted, including all patients who underwent elective colorectal resections with curative intent for malignant colorectal tumors between March 2017 and March 2023. Eligible patients had documented ABO blood group and Rh type, along with pathology reports from surgical specimens.
results. The study included 270 patients, with a median age of 74.5 years-old. The cohort was predominantly female (50.4%). Lymph node metastasis was observed in 156 patients (57.7%). A binary logistic regression model identified factors associated with lymphatic spread: rectal tumor location (OR: 3.85, 95% CI: 1.14–15.60), poorly differentiated tumors (OR: 6.84, 95% CI: 1.37–53.80), invasion depth T3 (OR: 4.88, 95% CI: 1.72–16.90) and T4 (OR: 16.20, 95% CI: 4.78–65.60), and extramural vein invasion (OR: 7.17, 95% CI: 1.37–53.80). Notably, the AB blood group (OR: 0.12, 95% CI: 0.01–0.65) was associated with a lower likelihood of lymph node metastasis, suggesting a potential protective effect. A separate binary logistic regression analysis evaluating factors related to MSI found no statistically significant associations, including for ABO blood group and Rh antigen.
conclusionsOur findings suggest that the AB blood group is associated with a reduced likelihood of lymph node metastasis compared to other blood groups. However, the existing literature on the relationship between blood group and lymph node metastasis is inconsistent. Further research is necessary to clarify the prognostic role of ABO blood group in colorectal cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.